Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Commercial Sponsor
Eli Lilly and Company
Summary
This is a randomised trial with experimental and active comparator arms. Participants in the Experimental Arm will receive Abemaciclib administered orally and standard adjuvant Endocrine Therapy (physician's choice) administered according to package label. Participants in the Active Comparator arm will receive a placebo administered orally and standard adjuvant Endocrine Therapy (physician's choice) administered according to package label.